|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Irritable bowel syndrome symptom severity improves equally with probiotic and placebo显示文摘AIM To determine the effects of Lactobacillus acidophilus NCFM on irritable bowel syndrome(IBS) symptoms and quality of life(Qo L).METHODS In this randomized triple-blind trial, adult IBS volunteerswho were recruited according to Rome Ⅲ criteria received 109 or 1010 colony-forming units of NCFM or placebo daily for 12 wk. IBS Symptom Severity Score(IBS-SSS), which constituted the primary outcome, and secondary outcomes, including individual IBS symptoms, IBS-related QoL questionnaire, anxiety and depression, defecation frequency, and stool consistency, were assessed at baseline at the end of the 8-wk runin period, after 4 and 12 wk of intervention, and after a 4-wk washout.RESULTS A total of 340 of 391 randomized volunteers completed the trial. IBS-SSS improved over 12 wk of treatment in all treatment groups, decreasing by a mean ± SD of 44.0 ± 80.2, 50.8 ± 82.4, and 48.3 ± 72.2 in the placebo, active low-dose, and active high-dose groups, respectively. Similarly, secondary outcomes did not differ between treatment groups. However, in a post hoc analysis of volunteers with moderate to severe abdominal pain at baseline(VAS > 35/100), the treatment significantly reduced the sensation of abdominal pain. Pain scores fell by 20.8 ± 22.8, 29.4 ± 17.9, and 31.2 ± 21.9 in the placebo, active low-dose, and active high-dose groups, respectively(P value for placebo vs combined active doses = 0.0460).CONCLUSION NCFM alleviates moderate to severe abdominal pain, consistent with earlier observations of this strain mitigating visceral pain through increased analgesic receptor expression. | Anna Lyra Markku Hillila Teppo Huttunen Sofia Mannikko Mikko Taalikka Julia Tennila Anneli Tarpila Sampo Lahtinen Arthur C Ouwehand Lea Veijola | 2016 | World Journal of Gastroenterology2016，22，48： | 7 |
| 2 | Faecal microbiota transplantation in patients with Clostridium difficile and significant comorbidities as well as in patients with new indications:A case series显示文摘Fecal microbiota transplantation(FMT) is effective in recurrent Clostridium difficile infection(r CDI). Knowledge of the safety and efficacy of FMT treatment in immune deficient patients is scarce. FMT has been suggested as a potential method for an increasing number of new indications besides r CDI. Among our FMT-treated r CDI patients, we reviewed those with major comorbidities: two human immunodeficiency virus patients, six haemodialysis patients, two kidney transplant patients, two liver transplant patients and a patient with chronic lymphatic leukaemia. We also reviewed those treated with FMT for indications other than r CDI: Salmonella carriage(two patients), trimethylaminuria(two patients), small intestinal bacterial overgrowth(SIBO;one patient), and lymphocytic colitis(one patient), as well as a common variable immunodeficiency patient with chronic norovirus infection and ESBL-producing Escherichia coli(E. coli) carriage. Of the thirteen r CDI patients treated with FMT, eleven cleared the CDI. The observed adverse events were not directly attributable to FMT. Concerning the special indications, both Salmonellas and ESBL-producing E. coli were eradicated. One trimethylaminuria patient and one SIBO-patient reported a reduction of symptoms. Three patients did not experience a benefit from FMT: chronic norovirus, lymphocytic colitis and the other fish malodour syndrome. There were no reported side effects in this group. FMT appeared to be safe and effective for immunocompromised patients with r CDI. FMT showed promise for the eradication of antibiotic-resistant bacteria, but further research is warranted. | Perttu Lahtinen Eero Mattila Veli-Jukka Anttila Jyrki Tillonen Matti Teittinen Pasi Nevalainen Seppo Salminen Reetta Satokari Perttu Arkkila | 2017 | World Journal of Gastroenterology2017，23，39： | 2 |
| 3 | Comparison of bacterial quantities in left and right colon biopsies and faeces显示文摘AIM:To compare quantities of predominant and pathogenic bacteria in mucosal and faecal samples.METHODS:Twenty patients undergoing diagnostic colonoscopy with endoscopically and histologically normal mucosa were recruited to the study,14 subjects of which also supplied faecal(F) samples between 15 d to 105 d post colonoscopy.Mucosal biopsies were taken from each subject from the midportion of the ascending colon(right side samples,RM) and the sigmoid(left side samples,LM).Predominant intestinal and mucosal bacteria including clostridial 16S rRNA gene clusters Ⅳ and ⅩⅣab,Bacteroidetes,Enterobacteriaceae,Bifidobacterium spp.,Akkermansia muciniphila(A.muciniphila),Veillonella spp.,Collinsella spp.,Faecalibacterium prausnitzii(F.prausnitzii) and putative pathogens such asEscherichia coli(E.coli),Clostridium difficile(C.difficile),Helicobacter pylori(H.pylori) and Staphylococcus aureus(S.aureus) were analysed by quantitative polymerase chain reaction(qPCR).Host DNA was quantified from the mucosal samples with human glyceraldehyde 3-phosphate dehydrogenase gene targeting qPCR.Paired t tests and the Pearson correlation were applied for statistical analysis.RESULTS:The most prominent bacterial groups were clostridial groups Ⅳ and ⅩⅣa+b andBacteroidetes and bacterial species F.prausnitzii in both sample types.H.pylori and S.aureus were not detected and C.difficile was detected in only one mucosal sample and three faecal samples.E.coli was detected in less than half of the mucosal samples at both sites,but was present in all faecal samples.All detected bacteria,except Enterobacteriaceae,were present at higher levels in the faeces than in the mucosa,but the different locations in the colon presented comparable quantities(RM,LM and F followed byP 1 for RMvs F,P 2 for LMvs F andP 3 for RM vs LM:4.17 ± 0.60 log 10 /g,4.16 ± 0.56 log 10 /g,5.88 ± 1.92 log 10 /g,P 1 = 0.011,P 2 = 0.0069,P 3 = 0.9778 forA.muciniphila;6.25 ± 1.3 log 10 /g,6.09 ± 0.81 log 10 /g,8.84 ± 1.38 log 10 /g,P 1 < 0.0001,P 2 = 0.0002,P 3 = 0.6893 forBacteroidetes;5.27 ± 1.68 log 10 /g,5.38 ± 2.06 log 10 /g,8.20 ± 1.14 log 10 /g,P 1 < 0.0001,P 2 ≤ 0.0001,P 3 = 0.7535 forBifidobacterium spp.;6.44 ± 1.15 log 10 /g,6.07 ±1.45 log 10 /g,9.74 ±1.13 log 10 /g,P 1 < 0.0001,P 2 ≤ 0.0001,P 3 = 0.637 forClostridium cluster Ⅳ;6.65 ± 1.23 log 10 /g,6.57 ± 1.52 log 10 /g,9.13 ± 0.96 log 10 /g,P 1 < 0.0001,P 2 ≤ 0.0001,P 3 = 0.9317 forClostridium cluster ⅩⅣa;4.57 ± 1.44 log10/g,4.63 ± 1.34 log10/g,7.05 ± 2.48 log 10 /g,P 1 = 0.012,P 2 = 0.0357,P 3 = 0.7973 for Collinsella spp.;7.66 ± 1.50 log 10 /g,7.60 ± 1.05 log 10 /g,10.02 ± 2.02 log 10 /g,P 1 ≤ 0.0001,P 2 = 0.0013,P 3 = 0.9919 forF.prausnitzsii;6.17 ± 1.3 log 10 /g,5.85 ± 0.93 log 10 /g,7.25 ± 1.01 log 10 /g,P 1 = 0.0243,P 2 = 0.0319,P 3 = 0.6982 for Veillonella spp.;4.68 ± 1.21 log 10 /g,4.71 ± 0.83 log 10 /g,5.70 ± 2.00 log 10 /g,P 1 = 0.1927,P 2 = 0.0605,P 3 = 0.6476 forEnterobacteriaceae).TheBifidobacterium spp.counts correlated significantly between mucosal sites and mucosal and faecal samples(Pearson correlation coefficients 0.62,P = 0.040 and 0.81,P = 0.005 between the right mucosal sample and faeces and the left mucosal sample and faeces,respectively).CONCLUSION:Non-invasive faecal samples do not reflect bacterial counts on the mucosa at the individual level,except for bifidobacteria often analysed in probiotic intervention studies. | Anna Lyra Sofia Forssten Peter Rolny Yvonne Wettergren Sampo J Lahtinen Krista Salli Lennart Cedgrd Elisabeth Odin Bengt Gustavsson Arthur C Ouwehand | 2012 | World Journal of Gastroenterology2012，18，32： | 2 |
| 4 | Transmission line corona losses under hoar frost conditions显示文摘 | Lahti K Lahtinen M | 1997 | IEEE Trans on Power Delivery1997，12，2： | 1 |
| 5 | Prenatal probiotic ad- ministration can influence Bifidobacterium microbiota develop- ment in infants at high risk of allergy 显示文摘 | Lahtinen SJ Boyle RJ Kivivuori S | 2009 | J Allergy Clin Immunol2009，123，2： | 1 |
| 6 | Heart rate and performance during combat missions in a flight simulator 显示文摘 | Lahtinen TM Koskelo JP Laitinen T | 2007 | Aviat Space Environ Med2007，78，4： | 1 |
| 7 | Binding of aflatoxin B1 to cell wall components of Lactobacillus rhamnosus strain GG显示文摘 | S. J. Lahtinen C. A. Haskard A. C. Ouwehand S. J. Salminen J. T. Ahokas | 2004 | Food Additives & Contaminants: Part A2004，，2： | 1 |
| 8 | Transmission line corona losses under hoar frost conditions显示文摘 | Lahti K Lahtinen M Nousiainen K | 1997 | IEEE Trans on Power Delivery1997，12，2： | 1 |
| 9 | Chemical state quantification of iron and chromium oxides using XPS the effect of the background subtraction method显示文摘 | ARONNIEMI M SAINIO J LAHTINEN J | 2005 | Surf Sci2005，578，13： | 1 |
| 10 | 显示文摘 | Kung K Y Lahtinen J | 1999 | J Mol Catal A:Chem1999，141，： | 1 |
| 11 | The chain extension of anionic prepolymers in the preparation of aqueous poly (urethane-urea) dis- persions显示文摘 | Lahtinen M Pinfield R K Price C | 2003 | Polymer International2003，52，6： | 1 |
| 12 | Somatostatin release in rat necortex during gamma- hydroxybutyrate- provoked seizures: microdialysis combined with EEG recording显示文摘 | Lahtinen H Barnkack J Koivisto E | 1992 | Brain Res Bull1992，29，6： | 1 |
| 13 | Degradation of 16S rRNA and attributes of viability of viable but nonculturable probiotic bacteria 显示文摘 | Lahtinen S J Ahokoski H Reinikainen J P | 2008 | Lett Appl Microbiol2008，46，6： | 1 |
| 14 | Sandpiles on Watts-Strogatz type small-worlds显示文摘 | Lahtinen J Kertész J Kaski K | 2005 | Physica A:Statistical and Theoretical Physics2005，349，34： | 1 |
| 15 | Identification of fuzzy controller for use with a falling-film evaporator显示文摘 | LahtinenS T | 2001 | Food Control2001，12，3： | 1 |
| 16 | GIC Occurrences and GIC Test for 400 kV System Transformer显示文摘 | LAHTINEN M ELOVAARA J | 2002 | IEEE Transactions on Power Delivery2002，17，2： | 1 |
| 17 | Binding of aflatoxin B1 to cell wall components of lactobacillus rhamnosus strain GG显示文摘 | Lahtinen S J Haskard C A Ouwehand A C | 2004 | Food Additives and Contami- nants2004，21，2： | 1 |
| 18 | Charac-terization for Water Vapour Barrier and Heat SealabilityProperties of Heat-treated Paperboard/Polylactide Structure显示文摘 | LAHTINEN K K0TKAM0 S KOSKINEN T | 2009 | Packag Technol Sci2009，22，： | 1 |
| 19 | An overview of the methods used in the characterisatlon of natural organic matter (NOM) in relation to drinking water treatment 显示文摘 | MATILAINEN A GJESSING E T LAHTINEN T | 2011 | Chemosphere2011，83，11： | 1 |
| 20 | The chain extension of anionic prepolyrners in the preparation of aqueous poly( urethaneurea) dispersions 显示文摘 | Lahtinen M Pinfield R K Price C | 2003 | Polym Int2003，52，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员